The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib

Proteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms of this resistance remain unclear. The aim of our study is to assess the expression...

Full description

Bibliographic Details
Main Authors: Pawel Robak, Dariusz Jarych, Damian Mikulski, Izabela Dróżdż, Edyta Węgłowska, Aleksandra Kotkowska, Małgorzata Misiewicz, Piotr Smolewski, Konrad Stawiski, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
bortezomib
CXCR4
gene expression
multiple myeloma
POMP
PSMB5
Online Access:https://www.mdpi.com/2072-6694/13/5/951

Internet

https://www.mdpi.com/2072-6694/13/5/951

Similar Items